RT Journal Article
SR Electronic
T1 Anosmia and dysgeusia in patients with mild SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.11.20055483
DO 10.1101/2020.04.11.20055483
A1 Levinson, Ruth
A1 Elbaz, Meital
A1 Ben-Ami, Ronen
A1 Shasha, David
A1 levinson, Tal
A1 Choshen, Guy
A1 Petrov, Ksenia
A1 Gadoth, Avi
A1 Paran, Yael
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.11.20055483.abstract
AB In this cohort of 42 patients with mild COVID19 we found a unique clinical feature of acute anosmia and dysgeusia in more than third of patients. Median onset of these features was 3.3 days after onset of illness (range 0-7) with rapid recovery in most patients.Article Summary Line Anosmia and dysgeusia appeared early in third of our patients with mild SARS-CoV-2 infection and were short-lived in most patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are in the manuscript.